Thus, the cell line can be used for developing methods for early diagnosis, for investigating new targeting therapy including ARID1A and FGFR3, and for examining the involvement of ARID1A and FGFR3 mutation in the development, survival, and progression of cancer. This evidence concerns the gene FGFR3 and cancer.